An alternative interpretation is that the increased levels of antibodies against EBNA6_0488 resulted from a putative CTCF overexpression during the disease progression in the cohort of ME/CFS patients with an infectious disease trigger. The gene discussed is CTCF; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.